Weight loss associated with semaglutide treatment among people with HIV.

Haidar L, Crane HM, Nance RM, Webel A, Ruderman SA, Whitney BM, Willig AL, Napravnik S, Mixson LS, Leong C, Lavu A, Aboulatta L and 12 more

Show all authors

Dai M, Hahn A, Saag MS, Bamford L, Cachay E, Kitahata MM, Mayer KH, Jacobson J, Moore RD, Delaney JAC, Drumright LN, Eltonsy S

AIDS (London, England)16 Nov 2023Cited by 15 (Europe PMC)

PMID37976053PMCIDPMC10922142DOI10.1097/qad.0000000000003791PepBankPUB-37976053

Source link PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
In adults with HIV, starting semaglutide was associated with an average weight loss of 6.47 kg at 1 year.
In plain wordsIn adults with HIV, semaglutide use was linked to an average weight loss of 6.47 kg after 1 year.
Peptide
Semaglutide
Outcome
DecreaseWithin-person body weight change at 1 year
Study
n = 222
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Weight loss
6.47 kg
1 year
Source sentences
Summary
treatment with semaglutide was associated with an average weight loss of 6.47 kg at 1 year (95% CI -7.67 to -5.18)
2 context sentences(design, population, supporting numbers)
Summary · context
Observational study using the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort.
Summary · context
We identified adult PWH who initiated semaglutide between 2018 and 2022 and with at least two weight measurements.
Report a problemFND-3797605301
02HumanObservational studyEfficacy outcome
In adults with HIV who had a postindex HbA1c value, starting semaglutide was associated with an HbA1c reduction of 1.07% at 1 year.
In plain wordsIn adults with HIV, semaglutide use was linked to a 1.07% lower HbA1c after 1 year.
Peptide
Semaglutide
Outcome
DecreaseWithin-person HbA1c change at 1 year
Study
n = 157
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
HbA1c reduction
1.07%
1 year
Source sentences
Summary
with a reduction in HbA1c of 1.07% at 1 year (95% CI -1.64 to -0.50) among the 157 PWH with a postindex HbA1c value.
2 context sentences(design, population, supporting numbers)
Summary · context
Observational study using the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort.
Summary · context
We identified adult PWH who initiated semaglutide between 2018 and 2022 and with at least two weight measurements.
Report a problemFND-3797605302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.